Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1001 - 1050 of 1864 results
- Internalizing Antibody-Based Targeted Gene Delivery for Human Cancer Cells.
- Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
- Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
- Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
- Thymic Stromal-Derived Lymphopoietin Induces Proliferation of Pre-B Leukemia and Antagonizes mTOR Inhibitors, Suggesting a Role for Interleukin-7R{alpha} Signaling.
- Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivo Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity In vivo.
- Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
- Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70.
- Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells.
- LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
- Bevacizumab in the treatment of ovarian cancer.
- Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy.
- Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
- Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas.
- Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
- Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
- Bortezomib down-regulates the cell surface expression of HLA-class I and enhances natural killer cell-mediated lysis of myeloma.
- Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
- Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB.
- Oncolytic adenovirus Ad5/3-Delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
- Nanotherapeutics for enhancing thermal therapy of cancer.
- Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-)) mice.
- Construction and Characterization of Single-chain Antibodies against Human Insulin-like Growth Factor-I Receptor from Hybridomas Producing 1H7 or 3B7 Monoclonal Antibody.
- A chimeric SM5-1 antibody inhibits hepatocellular carcinoma cell growth and induces caspase-dependent apoptosis.
- SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene.
- Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
- Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion.
- Immunotherapy of cancer by IL-12-based cytokine combinations.
- L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer.
- Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada.
- Potential effects of decreased cervical cancer screening participation after HPV vaccination: An example from the U.S.
- Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.
- Dasatinib, a small molecule protein tyrosine kinase inhibitor, inhibits T cell activation and proliferation.
- Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner.
- Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.
- In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer.
- An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression.
- 5-Fluorouracil, Leucovorin and Oxaliplatin plus Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer: A Single-Institute Study.
- Activation of Toll-like Receptor 4 on Tumor Cells In vitro Inhibits Subsequent Tumor Growth In vivo.
- In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab.
- Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting.
- Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification.
- An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer.
- Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion.
- A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer.
- DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity.
- A Cellular Trojan Horse for Delivery of Therapeutic Nanoparticles into Tumors.
- An Anti-Double-Stranded DNA Monoclonal Antibody Induced by Tumor Cell-Derived DNA Inhibits the Growth of Tumor In Vitro and In Vivo via Triggering Apoptosis.
- Efficient Systemic Expression of Bioactive IL-15 in Mice upon Delivery of Optimized DNA Expression Plasmids.